Opinion|Videos|November 25, 2024
An Overview of the Molecular Characterization of Lung LCNEC
Author(s)Martin Dietrich, MD, PhD, Soo-Ryum Yang, MD
Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.
Advertisement
Episodes in this series
- Dr. Dietrich to Dr. Yang:
- How has the characterization and classification of lung LCNEC evolved in the past decade?
- Can you describe the clinical heterogeneity of these tumors?
- How do you navigate this in practice?
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5